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Supplementary Table S3; Al-Qaoud et al, AJKD, “Socioeconomic Status and Reduced Kidney Function 
in the Whitehall II Study: Role of Obesity and Metabolic Syndrome” 
Table S3. Age and lean mass index (LMI) adjusted odds ratios (95% confidence intervals (CI)) 
by sex for the associations between decreased GFR (eGFR <60 ml/min/1.73m2 derived from 
IDMS calibrated CKD-EPI formula) and body-mass index (BMI), and components of the 
metabolic syndrome amongst sample with impedance measurements (each row refers to a 
separate model on the same set of participants)  
 Men (N=3627) Women (N=1211) 
Factor Odds ratio (95%CI) p-value Odds ratio (95%CI) p-value 
Occupational grade (per grade increase) 0.99 (0.77 to 1.29) 0.9 1.51 (1.03 to 2.23) 0.04 
BMI** (weight(kg)/height(m2)) 
Overweight 
Obese 
 
1.62(1.16 to 2.27) 
1.38(0.83 to 2.30) 
 
0.005 
0.2 
 
2.07(1.04 to 4.09) 
2.41(1.05 to 5.54) 
 
0.04 
0.04 
Waist circumference* (cm) 
Q2 
Q3 
Q4 
 
1.63(1.05 to 2.53) 
1.79(1.16 to 2.76) 
1.57(0.98 to 2.50) 
 
0.02 
0.008 
0.06 
 
1.21(0.56 to 2.62) 
0.92(0.40 to 2.10) 
1.17(0.49 to 2.80) 
 
0.6 
0.8 
0.7 
Systolic BP* (mmHg) 
Q2 
Q3 
Q4 
 
0.61(0.40 to 0.92) 
0.60(0.40 to 0.91) 
0.99(0.68 to 1.43) 
 
0.01 
0.01 
0.9 
 
0.51(0.24 to 1.09) 
0.69(0.35 to 1.38) 
0.36(0.15 to 0.84) 
 
0.08 
0.3 
0.02 
Diastolic BP* (mmHg) 
Q2 
Q3 
Q4 
 
0.71(0.47 to 1.06) 
0.88(0.60 to 1.30) 
1.23(0.84 to 1.81) 
 
0.1 
0.5 
0.3 
 
0.59(0.29 to 1.19) 
0.36(0.15 to 0.86) 
0.80(0.40 to 1.58) 
 
0.1 
0.02 
0.5 
HDL cholesterol* (mg/dL) 
Q2 
Q3 
Q4 
 
0.60(0.42 to 0.87) 
0.55(0.35 to 0.86) 
0.45(0.30 to 0.67) 
 
0.007 
0.009 
<0.001 
 
0.68(0.34 to 1.36) 
0.60(0.30 to 1.23) 
0.55(0.24 to 1.25) 
 
0.3 
0.2 
0.2 
Triglycerides* (mg/dL) 
Q2 
Q3 
Q4 
 
1.57(1.03 to 2.39) 
2.07(1.39 to 3.08) 
2.57(1.67 to 3.96) 
 
0.03 
<0.001 
<0.001 
 
0.82(0.32 to 2.08) 
2.08(1.03 to 4.20) 
1.84(0.89 to 3.79) 
 
0.7 
0.04 
0.09 
Fasting glucose* (mg/dL) 
Q2 
Q3 
Q4 
 
1.10(0.73 to 1.65) 
0.99(0.65 to 1.49) 
1.17(0.79 to 1.73) 
 
0.6 
0.9 
0.4 
 
0.72(0.36 to 1.43) 
0.67(0.31 to 1.42) 
0.70(0.33 to 1.47) 
 
0.3 
0.3 
0.4 
Diabetes prevalence  (yes vs. no) 1.75 (1.20 to 2.57) 0.004 0.74(0.32 to 1.72) 0.5 
*Sex specific quartiles of factors, OR demonstrate comparison to lowest quartile (Q1) 
**BMI OR demonstrate comparison to participants in underweight/normal category 
-Abbreviations: BMI: body mass index, BP: blood pressure, HDL: high density lipoprotein cholesterol. 
-Conversion factors: HDL cholesterol mg/dL to mmol/L, x 0.02586; Triglycerides mg/dL to mmol/L, x 
0.01129; Fasting glucose mg/dL to mmol/L, x 0.05551    
 
 
